The long term efficacy of glycyrrhizin in chronic hepatitis C patients

Cancer

Volumn 79, Issue 8, 1997, Pages 1494-1500

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Murashima, Naoya ^a   Chayama, Kazuaki ^a   Tsubota, Akihito ^a   Koida, Isao ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

chronic hepatitis C; glycyrrhizin; hepatocellular carcinoma; Stronger Neo Minophagen C

Indexed keywords

GLYCYRRHIZIC ACID; INTERFERON; NEOMINOPHAGEN C;

ADULT; ARTICLE; CANCER PREVENTION; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; FEMALE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; JAPAN; LIVER NEOPLASMS; LONG-TERM CARE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0031002861     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B     Document Type: Article

References (26)

1. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogeneses: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
2. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma with cirrhosis. Hepatology 1990;12:680-7.
3. Ikegami T, Sugiura N, Ebara M, Saisho H, Ohto M. Development and predictive factors of hepatocellular carcinoma in patients with chronic liver disease over a long follow-up period [in Japanene]. Jpn J Gastroenterol 1994;91:1290-300.
4. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
5. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim R, et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to. Cancer 1995;76:743-9.
6. Utsumi K. Action of glycyrrhizin on biomembrane [in Japanese]. Proc Symp Liver and Glycyrrhizin. 1984;104.
7. Watari N. An electronmicroscopic study of the effects of glycyrrhizin on experimentally injured liver. Mini Med Rev 1973;11:12-7.
8. Kumagai A, Tamura Y, Nishikawa T. Research on the mechanism of electrolytic action of glycyrrhizin and its prevention [in Japanese]. Pharmacol Ther 1979;7:2933.
9. Ichikawa O, Saitoh Y, Yukimura T, Kawamata F. Research on inhibition of experimental allergic reactions due to Stronger Neo-Minophagen C [in Japanese]. Rep Minophagen Res Div 1950;160:1.
10. Yamamoto S, Maekawa Y, Imamura M, Hisajima T. Treatment of hepatitis with the antiallergic drug, Stronger Neo-Minophagen C [in Japanese]. Clin Med Pediatr 1958;13:73.
11. Suzuki H, Ohta T, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double-blind trial. Asian Med J 1983;26:423-38.
12. Hino L, Miyakawa H, Takahashi J, Kumada H, Ikeda K, Yoshiba A, et al. Effect of large dose of SNMC on the liver histology of chronic active hepatitis [in Japanese]. Kan-Tansui 1986;13:797.
13. Yasuda K, Hino K, Fujioka S, Kaku K, Fukuhara A, Nashida Y, et al. Effects of high dose therapy with Stronger Neo-Minophagen C (SNMC) on hepatic histography in non-B chronic active hepatitis. Elsevier Science Publishers B. V. (Biomedical Division) 1991:205-9.
14. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biomedaica 1983;62:553-66.
15. Chayama Y, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993;8:150-6.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
17. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-75.
18. Dixon WJ, Brown MB, Engleman L, et al. BMDP Statistical software. Berkeley: University of California, 1985.
19. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Peters M, et al. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315:1575-8.
20. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration or serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
21. Arase Y, Kumada H, Chayama K, Tsubota A, Ikeda K, Saitoh S, et al. Alanine aminotransferase and HCV-RNA responses following Interferon therapy of HCV-RNA positive chronic hepatitis. Gastroenterol Japonica 1992;27:646-51.
22. Tsubota A, Chayama K, Arase Y, Saitoh S, Koida I, Ikeda K, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993;8:535-9.
23. Hino K, Sainokami S, Shimoda K, Iino S, Yu Wang, Okamoto H, et al. Genotypes and titers of Hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
24. Arase Y, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, et al. The superiority of laparoscopic examination in predicting hepatocellular carcinoma after interferon therapy for chronic type C hepatitis. Dig Endose J Pharmacol. 1962;10:613-20. In press.
25. Finney RSH, Somers GF. The anti-inflammatory activity of glycyrhetinic acid derivatives. J Pharmacol 10:613-20.
26. Ohuchi K, Tsurufuji A. A study of the anti-inflammatory mechanism of glycyrrhizin. Mino Med Rev 1982;27:188-93.